Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Neutral
Website
N/ATelephone
61.2.9209.4037
Address
4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015
Description
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.86 - 6.5
Trade Value (12mth)
AU$606,994.00
1 week
0.32%
1 month
23.77%
YTD
199.51%
1 year
610.06%
All time high
6.50
EPS 3 yr Growth
248.500%
EBITDA Margin
N/A
Operating Cashflow
-$27m
Free Cash Flow Return
-34.10%
ROIC
-30.50%
Interest Coverage
N/A
Quick Ratio
10.20
Shares on Issue (Fully Dilluted)
263m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
16 July 24 |
Supply agreement for Ac-225 with TerraPower Isotopes
×
Supply agreement for Ac-225 with TerraPower Isotopes |
24 June 24 |
Clarity Receives $10 million R&D Tax Incentive
×
Clarity Receives $10 million R&D Tax Incentive |
20 June 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
20 June 24 |
Cleansing Notice
×
Cleansing Notice |
07 June 24 |
Clarity Confirms No Supply Disruptions for Clinical Trials
×
Clarity Confirms No Supply Disruptions for Clinical Trials |
05 June 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
05 June 24 |
Cleansing Notice
×
Cleansing Notice |
30 May 24 |
Clarity strengthens Cu-64 network with new supply agreement
×
Clarity strengthens Cu-64 network with new supply agreement |
22 May 24 |
Change of Director's Interest Notice - Rob Thomas
×
Change of Director's Interest Notice - Rob Thomas |
17 May 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
17 May 24 |
Cleansing Notice
×
Cleansing Notice |
03 May 24 |
Clarity to Present at 3 World Leading Conferences
×
Clarity to Present at 3 World Leading Conferences |
03 May 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
03 May 24 |
Cleansing Notice
×
Cleansing Notice |
30 April 24 |
Complete response with Cu-67 SAR-bisPSMA
×
Complete response with Cu-67 SAR-bisPSMA |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 April 24 |
Change of Director's Interest Notice - Thomas
×
Change of Director's Interest Notice - Thomas |
29 April 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
24 April 24 |
Successful Completion of Retail Entitlement Offer
×
Successful Completion of Retail Entitlement Offer |
15 April 24 |
Change in substantial holding - Cabbit Pty Ltd
×
Change in substantial holding - Cabbit Pty Ltd |
15 April 24 |
Ceasing to be a substantial holder - Taylor
×
Ceasing to be a substantial holder - Taylor |
15 April 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
15 April 24 |
Cleaning Notice
×
Cleaning Notice |
15 April 24 |
Change in substantial holding
×
Change in substantial holding |
08 April 24 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.